• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of thoraxThoraxInstructions for authorsInstructions for authors
Thorax. Mar 2007; 62(3): 200–210.
PMCID: PMC2117156

Intermediate care—Hospital‐at‐Home in chronic obstructive pulmonary disease: British Thoracic Society guideline

Intermediate care is a treatment model which bridges the interface between hospital and community care. It often involves cooperation between hospital doctors, general practitioners, nurses, physiotherapists and other healthcare professionals. A specific subtype of intermediate care is Hospital‐at‐Home (HaH), where active treatment is provided by healthcare professionals in the patient's home for a condition that otherwise would require hospital care, always for a limited period.

In 2003 a Cochrane systematic review concluded that HaH was a safe and effective treatment approach for selected patients with exacerbations of chronic obstructive pulmonary disease (COPD), and suggested that one in four patients presenting to hospital as an emergency would be suitable for home treatment with nursing support,1 although some felt that this was an underestimate of eligibility for HaH (Stevenson, 2005).

In 2004 the National Institute for Clinical Excellence (NICE) COPD guidelines2 included appraisal of HaH in exacerbations of COPD. A distinction was made between HaH (where hospital admission was avoided) and assisted or early discharge schemes (where a short initial admission was followed by home care). We suggest that it is illogical to exclude cases of early or assisted discharge from HaH and, in this guideline, we will consider HaH as a treatment modality which encompasses both admission avoidance and early supported discharge.

The NICE guideline identified four randomised controlled trials (RCTs) and one service evaluation which were applicable to admission avoidance for patients with exacerbations of COPD, and one RCT related to early supported discharge.

The evidence statements can be summarised as follows:

  • There were no significant differences in forced expiratory volume in 1 second (FEV1),3,4,5 readmission rates,3,4,5,6 mortality4,5,6 or number of days in care5 between HaH and hospital care.
  • Two studies showed no difference between the groups for health status,3,4 but a Spanish study showed improvement in St George's Respiratory Questionnaire (SGRQ) in the HaH group.6 One study showed no difference between the groups for symptom scores5 and, in the same study, there was no difference in satisfaction scores for either patients or carers.
  • One study found that reducing inpatient stay from 6.1 to 3.2 days by using supported discharge was not associated with any increase in readmission rate or mortality.7
  • There was no convincing evidence that HaH was either more or less expensive than conventional care.

Recommendations from NICE guidelines

The recommendations from the NICE guidelines are shown in table 11,, but leave many unanswered questions:

Table thumbnail
Table 1 Recommendations from the NICE guidelines
  • How, where and by whom should patients be assessed for suitability for HaH?
  • Should HaH aim to avoid admission or to implement early supported discharge?
  • Should the service be limited to 9:00 to 17:00 hours Monday to Friday or should its hours of operation be more extended?
  • What proportion of patients with exacerbations of COPD will be suitable for HaH?
  • Should the HaH team be composed of specialist practitioners or could it be generic?
  • Does HaH require modification of treatment policy?
  • What competencies are necessary to deliver HaH?
  • What should comprise home care?
  • How many visits will be necessary and for how long?
  • Would stable COPD patients benefit from intermediate care?

This guideline will attempt to answer the above questions so that both existing services may be modified and also that new services may be set up in the light of the present evidence base.

Methods

The methodology recommended by NICE Guideline Development Methods was used to develop these guidelines (http://www.nice.org.uk/page.aspx?o = guidelinestechnicalmanual). A systematic literature review was performed for relevant studies between 1966 and April 2005 searching the following databases: MEDLINE, CINAHL, EMBASE, Cochrane, ACP Journal Club, DARE and CCTR. Additional contemporary articles including those published since April 2005 were identified by the Guideline Development Group on an ad hoc basis. The levels of evidence and recommendations are described using the system used in the NICE COPD guidelines,2 since the HaH guideline is an amplification of one aspect of the main guideline, and are defined in table 22.

Table thumbnail
Table 2 Levels of evidence and recommendations2

Glossary of terms

ATS, American Thoracic Society

BTS, British Thoracic Society

COPD, chronic obstructive pulmonary disease

ESD, early supported discharge

ERS, European Respiratory Society

FEV1, forced expiratory volume in 1 second

Fio2, fractional inspired oxygen concentration

HaH, Hospital‐at‐Home

HRQoL, health related quality of life

ICP, integrated care pathway

RCT, randomised controlled trial

Spo2, oxygen saturation

SGRQ, St George's Respiratory Questionnaire

Summary of key priorities for implementation

The Guideline Development Group felt that the first priority was to resolve the uncertainties experienced by hospitals intending to set up HaH for exacerbations of COPD. Secondly, the Group hoped to provide advice to hospitals where HaH had been established but were encountering difficulties. Thirdly, it was considered important to define the role of intermediate care in stable COPD.

  1. HaH should be offered to patients with exacerbations of COPD unless there is impairment of consciousness, confusion, acidosis, serious co‐morbidity or inadequate social support.
  2. After suitability for HaH is confirmed by assessment in hospital, a treatment package is prescribed which includes antibiotics, steroids, nebulised bronchodilators and oxygen if necessary.
  3. Home care should be delivered by specialist respiratory nurses/physiotherapists or in generic teams by district nurses.
  4. For most hospitals the preferred model of HaH should be early supported discharge (ESD) rather than admission avoidance.
  5. The role of intermediate care in stable COPD is not yet clearly defined and initiatives in this area should be conducted as experimental and controlled interventions.

Assessment

There are several objectives of the assessment process when referred a patient for home management of exacerbation of COPD:

  1. Confirm the patient has COPD.
  2. Confirm the patient has an exacerbation.
  3. Determine that it is safe to manage the patient at home.
  4. Tailor the treatment to the patient and the exacerbation.

Assessment proformas/protocols/integrated care pathways

Several studies have shown that integrated care pathways (ICPs) can improve the delivery of care. This has been demonstrated by RCTs in the areas of inpatient asthma management, pneumonia, stroke rehabilitation, heart failure and orthopaedic surgery.8,9,10,11,12,13 Given the stereotyped nature of assessment and treatment in exacerbations of COPD, it is a potential area in which to use an ICP, but there have been no trials of this. Most ESD services use assessment proformas, although some have more detailed protocols (Angus, 2005). Examples of such documents can be viewed on the BTS website (http://www.brit‐thoracic.org.uk/). [Level of evidence IV]

Recommendation

  • (R1) A hospital should use an assessment proforma, protocol or ICP if setting up an integrated care service in order to deliver uniform care and facilitate audit. [Grade D]

The decision to treat at home

In making this decision, several questions need to be asked:

  • During the period of the exacerbation, patients are likely to need increased social or nursing input to enable them to manage their essential activities of daily living. Can this be provided by relatives, social services and respiratory liaison nurses? Can the patients rapidly and easily obtain help should they deteriorate?
  • Can additional pharmacological treatment be delivered in the home environment? The major issues are compliance, ability to operate a nebuliser or oxygen cylinder unsupervised and current smoking status if oxygen is required.
  • Is it possible to identify patients at high risk of rapid decline or failure to cope such that they should not be offered home treatment?

On the last question, many studies have demonstrated factors which identify group characteristics of patients at an increased risk of relapsing or requiring admission to hospital during an exacerbation of COPD.14,15,16,17,18,19,20,21,22,23,24,25

Such factors include:

  • increasing age;
  • longer duration of COPD;
  • severity of impairment of FEV1;
  • frequency of exacerbations;
  • chronic mucus hypersecretion;
  • co‐morbidity (especially heart disease);
  • use of home oxygen or maintenance steroids;
  • failure of first‐line treatment;
  • previous history of relapses;
  • generalised debility or malnutrition.

However, the models developed from these risk factors to predict relapse show only moderate sensitivity and specificity14,26 and are of marginal usefulness when faced with individuals. In a descriptive study of intermediate care for COPD,27 the initial severity of the exacerbation was similar among those treated at home and those who later required admission.

The RCTs looking at HaH for exacerbations of COPD have taken a pragmatic approach in deciding which patients can be managed at home. Since they have repeatedly shown no increase in admission/readmission rates, it is likely that their criteria for managing at home are safe.

The least restrictive set of absolute criteria for admission which were used in three studies3,6,7 were impaired level of consciousness, acute confusion, pH <7.35, acute changes on the chest radiograph, a concomitant medical problem requiring inpatient stay, insufficient social support, no telephone and residence geographically removed from hospital.

Some of the studies were slightly more prescriptive and required an ECG to be performed,4 or excluded subjects with any respiratory failure28 or those with newly diagnosed type 2 respiratory failure.5[Level of evidence III]

Recommendations

HaH should not be offered to patients with:

  • (R2) Impaired level of consciousness. [Grade C]
  • (R3) Acute confusion. [Grade C]
  • (R4) pH <7.35, if arterial blood gases have been measured. [Grade C]
  • (R5) Acute changes on chest radiograph. [Grade C]
  • (R6) Concomitant medical problem requiring inpatient stay. [Grade C]
  • (R7) Insufficient social support, no telephone, residence geographically removed from hospital. [Grade C]
  • (R8) New hypoxaemia (Spo2 [less-than-or-eq, slant]90%)–a contraindication if oxygen cannot be provided at home. [Grade D]

Venous blood tests

Venous blood tests may help in some cases to clarify the cause or contributory factors of an exacerbation or help in guiding treatment. The frequency with which such tests affect management in exacerbations of COPD has not been the subject of a study and therefore they are not routinely recommended. [Level of evidence IV]

Recommendation

  • (R9) Blood tests need not be routinely performed when considering patients for home management of their exacerbation but should be available if they are indicated after assessment. [Grade D]

Sputum analysis

The use of sputum microbiology to guide treatment of an exacerbation of COPD has not been the subject of a study. It is known that the airways of a proportion of patients with stable COPD are chronically colonised with bacteria and consequently an organism cultured during an exacerbation may not be causal.29,30 Similarly, the spectrum of antibiotic‐responsive organisms commonly causing exacerbations is well known without the need for culture.18 Consequently, the NICE guideline2 recommends routine sputum culture only for patients admitted to hospital and when the sputum is purulent.

Recommendation

  • (R10) Routine sputum culture before referral to HaH is not necessary. [Grade D]

ECG

The usefulness of an ECG has not been the specific subject of a study in exacerbations of COPD. In the absence of specific symptoms or signs such as chest pain or arrhythmia, it is unlikely that this test would alter management. [Level of evidence IV]

Recommendation

  • (R11) An ECG need not be routinely performed when considering patients for home management of their exacerbation but is indicated if the resting heart rate is <60/min or >110/min. [Grade D]

Arterial blood gases and pulse oximetry

According to the NICE guidelines2:

  • supplemental oxygen therapy should be given in exacerbations of COPD to maintain Spo2 >90% and <94%; and
  • patients with hypercapnic respiratory failure with an arterial blood pH <7.35 should be considered for ventilatory support.

Since oxygen therapy can cause decompensation of respiratory failure in COPD, arterial blood gas measurements should be performed before and after 1 hour on the flow rate of oxygen on which it is intended to send the patient home. [Level of evidence NICE]

Recommendation

  • (R12) Pulse oximetry should be performed on all subjects being considered for home management. Arterial blood gas measurements should be performed if Spo2 is [less-than-or-eq, slant]90%. These should be repeated after 1 hour on the intended therapeutic flow rate of oxygen aiming for 90% <Spo2 <94% and an arterial blood pH >7.35. [Grade NICE]

Chest radiography

In patients presenting to hospital with an exacerbation of COPD, performance of chest radiography leads to a change in management in 7–21% of patients.31,32,33 In the population of patients considered for HaH, this figure is likely to be lower as these patients are less acutely unwell. However, as the principal differential diagnoses are detectable on a chest radiograph (pneumonia, pneumothorax, pulmonary oedema),34 this test remains important. [Level of evidence IV]

Recommendation

  • (R13) A chest radiograph should be performed on all subjects being considered for home management. [Grade D]

Spirometry

Spirometry is important in confirming the diagnosis of COPD and, unless confused or comatose, even the sickest of patients can attempt an FEV1 manoeuvre. [Level of evidence IV]

Recommendation

  • (R14) Baseline spirometry should be carried out to confirm the diagnosis in cases where this is the patient's first presentation with presumed COPD. [Grade D]

Details of service

The RCTs which have shown that HaH for COPD exacerbations is a safe and effective alternative to conventional inpatient treatment have used different methodologies, and no studies have compared the relative effectiveness of the various HaH models. Here we describe the different types of service provision and identify which models may be the most suitable in particular hospital settings.

Types of service

1. Admission avoidance following A&E attendance

This model is described in RCTs from Edinburgh3 and Liverpool.4 Patients were assessed in the A&E department by standby specialist respiratory staff, including both nurses and doctors. If admission was not considered mandatory, they were allowed home with a treatment package and follow‐up on subsequent days by nurses was arranged.

In Edinburgh, eligibility for HaH was 29%. Hospital admission was necessary for 7% of patients randomised to the HaH scheme before they had been discharged from HaH. In Liverpool, eligibility for HaH was 33% and admission was necessary for 9% of the HaH patients within 2 weeks of randomisation to the HaH scheme. The readmission rate at 8 weeks in the Edinburgh study was 25% for HaH patients and 34% for controls, and in the Liverpool study at 3 months was 31% for HaH patients and 32% for controls.

This type of scheme requires high staffing levels and is most suited to busy inner city hospitals. [Level of evidence 1b]

2. Admission avoidance following direct GP referral

This model was described in an observational study from Glasgow.27 Local GPs referred patients directly to the respiratory department of the hospital where they were assessed on the same day by a respiratory nurse and a respiratory trainee doctor. Eligibility for HaH was 80% and 15% were admitted from HaH.

One study based on direct GP referral carried out assessment in the patient's home by a nurse or physiotherapist and did not include plain chest radiography. Eligibility for HaH was very high (only 1.5% of patients were not considered suitable) and 6% were admitted later from HaH.35

These schemes suffer from significant numbers of inappropriate referrals although some early exacerbations may be aborted. [Level of evidence III]

3. Early supported discharge (ESD)

This model was described in studies from Glasgow7 and Hull.5 Patients admitted with exacerbations of COPD were assessed on the morning after admission by the respiratory team, which therefore did not need to be available to see patients throughout the day. The readmission rate at 60 days in the Glasgow study was 29% for HaH patients and 30% for controls, and in the Hull study at 3 months the readmission rate was 33% for HaH patients and 44% for controls.

Eligibility for HaH was slightly higher than in admission avoidance schemes: 38% in Glasgow and 36% in Hull. Early inpatient assessment after a period of hospital care may therefore increase eligibility for HaH. Furthermore, recruitment for early supported discharge after admission allows the HaH team to plan its activity economically. [Level of evidence 1b]

4. Combination of admission avoidance and ESD

This model was described in an RCT from Barcelona.6 Patients were assessed in the emergency room by a specialised respiratory team. Admission was avoided in 68% of the HaH patients and, in those admitted, the length of stay was reduced to 1.7 days compared with 4.2 days in the control group. Eligibility for HaH was 39% and 10% were readmitted from the emergency room. [Level of evidence 1b]

A similar combined approach was used in an observational study from Southend in England where a generic rather than a specialised respiratory team carried out HaH.36 Eligibility for HaH was not shown, but the outcome measures were otherwise similar to those with specialised teams. [Level of evidence III]

Second UK COPD audit (2003)37

In this audit 44% of hospitals had access to ESD and, in these, eligibility for ESD was 31%. The types of service in the hospitals with ESD were:

  • Admission avoidance from A&E: 5%
  • Early supported discharge (<48 hours): 26%
  • Supported discharge (>48 hours): 23%
  • Combination of above: 12%
  • Unknown: 34%

Recommendations

  • (R15) In busy inner city hospitals, if staffing levels permit, the combined approach of admission avoidance and early supported discharge is practicable but might be expensive. Eligibility for HaH varies from 30% to 35% with readmission from home care of 10%. [Grade A]
  • (R16) In hospitals with fewer admissions for COPD or limited respiratory staffing levels, early inpatient assessment for supported discharge is the favoured model for HaH. Eligibility for HaH varies from 35% to 40%. [Grade A]
  • (R17) Recruitment for HaH following direct GP referral is not recommended because of large numbers of inappropriate referrals. [Grade C]

Hours of operation

1. Admission avoidance schemes

The models designed to recruit patients from A&E had variable hours of operation. In Edinburgh the team worked from 09:00 hours to 17:00 hours, Mondays to Fridays.3 In Liverpool the service operated from 08:00 hours to 18:00 hours 7 days a week,4 and in Barcelona the hours of service were 09:00 hours to 16:00 hours on weekdays only.6 In the 2nd UK COPD audit,37 64% of units ran a 5 day service and 27% had a 7 day scheme.

Unless a 24 hour service or next day review approach is adopted, a proportion of the patients will be missed by the HaH programme. The Edinburgh authors predicted that a full service available at all times would be able to support 150 out of 700 patients per year compared with 115 out of 500 presenting on weekdays only.3 In many hospitals the majority of COPD admissions occur in the early evening, and services based on the normal working day will therefore fail to recruit many patients for whom admission avoidance may be possible. [Level of evidence IV]

2. Early supported discharge schemes

Services designed to deliver early supported discharge can function on a 09:00 to 17:00 hour basis, but there will be a delay in assessment at weekends unless a 7 day service is used. [Level of evidence III]

Recommendations

  • (R18) For inner city hospitals with high COPD admission rates, a 24 h/7 day service should be set up in order to maximise admission avoidance. [Grade C]
  • (R19) For hospitals with fewer COPD admissions, hours of operation should correspond to the peak times of COPD referrals and a Monday to Friday service may be most cost effective. [Grade C]

A summary of HaH approaches in COPD is shown in table 33.

Table thumbnail
Table 3 Summary of HaH approaches in COPD

Overall responsibility

In general, out‐of‐hours cover and responsibility for the patient has remained with the hospital‐based HaH service although, in one study, patients were advised to contact their GP if problems arose out‐of‐hours.7 The authors did not report how this arrangement impacted on primary care services. All schemes have included assessment by a respiratory physician before recruitment to HaH. Patients are usually discharged from the service by the respiratory practitioner who has been supervising the home care. At that stage clinical responsibility is formally transferred back to primary care either by fax or email. [Level of evidence III]

Recommendations

  • (R20) After recruitment to HaH, clinical responsibility and out‐of‐hours cover should be undertaken by the acute trust. [Grade C]
  • (R21) When the patient is discharged from HaH, clinical responsibility should be formally transferred back to primary care either by fax or by email. [Grade C]

Team composition

The medical lead in all teams which have published their results has come from a consultant respiratory physician, backed up by junior respiratory trainees. Respiratory nurse specialists have been members of the HaH team in all published randomised trials. Respiratory physiotherapists also participate in several UK schemes.38

Generic HaH models have been described in which home care is provided by non‐specialist district nurses.28,36,39 Two of these were small RCTs28,39 and the other an observational study.36 In the latter, the initial assessment was carried out by specialised respiratory staff and the results were broadly similar to the findings in the RCTs where HaH was delivered by specialist respiratory practitioners.3,4,5,6,7

In the 2nd UK COPD audit,37 81% of the schemes were run primarily by respiratory nurses, 11% by general nurses, 2% by physiotherapists and 2% by both physiotherapists and nurses. [Level of evidence III]

Recommendations

  • (R22) The lead clinician should be a consultant respiratory physician, supported by trainee junior medical staff. [Grade C]
  • (R23) The home care team should be lead by a specialist respiratory nurse, physiotherapist or appropriately qualified health professional. [Grade C]
  • (R24) Inner city hospitals should aim for specialist teams, but district general hospitals in provincial or rural areas should consider generic teams which may deal with several HaH services. [Grade C]

Home care team competencies

None of the published studies has dealt with the skills which are necessary for the home care nurses and physiotherapists. The following recommendations are based on the consensus view of the Guideline Development Group. [Level of evidence IV]

Recommendations

  • (R25) Key skills for members of the HaH teams include:
    • ability to take a comprehensive clinical history;
    • proficiency in assessing clinical condition;
    • familiarity with pharmacological and non‐pharmacological approaches;
    • knowledge of current guidelines in COPD management;
    • excellent communication skills;
    • excellent team working skills. [Grade D]
  • (R26) Useful but non‐essential team member skills include:
    • ability to perform chest auscultation;
    • venous and arterial blood sampling;
    • performance of and basic interpretation of an ECG;
    • interpretation of a chest radiograph;
    • performance of spirometry;
    • understanding of airway clearance techniques. [Grade D]

Assessment at home after recruitment into HaH scheme

None of the published studies has critically evaluated the various aspects of assessment at home during HaH. However, there is general agreement that the first visit should be on the day after recruitment to HaH and subsequent visits arranged as considered necessary by the respiratory practitioner. In one study, visits were carried out twice daily for the first 3 days.4 In most studies, dyspnoea, cough, sputum colour/volume and vital signs were recorded. Oxygen saturation was measured by oximetry.

The studies on the role of oral steroids in exacerbations have used changes in FEV1 as an outcome measure and have shown that this measurement can detect recovery from an exacerbation.40 Furthermore, a low FEV1 value at admission associated with failure to improve over the first few days of an exacerbation in hospital was highly predictive of a poor clinical outcome.41 In some HaH studies spirometry was carried out using portable electronic spirometers,7,27 but was not always considered essential.36 It is, however, recommended before discharge.2

Telephone contact via the respiratory practitioner's mobile phone was encouraged6,42 and a copy of the clinical notes left with the patient to assist the general practitioner if called in an emergency.27 In two studies there were weekly team meetings with the hospital respiratory physician.3,6 In an inner city scheme, each nurse visited 5–6 patients daily usually in the mornings with an average of 2–3 assessments carried out in the hospital in the afternoons (Stevenson, 2005). [Level of evidence IV]

Recommendations

  • (R27) The first visit should be carried out on the day after recruitment to HaH. [Grade D]
  • (R28) Details of level of dyspnoea, cough and sputum volume/colour should be recorded. [Grade D]
  • (R29) Vital signs including pulse, BP, respiratory rate and temperature should be measured. [Grade D]
  • (R30) Oxygen saturation should be measured by oximetry and the Spo2 documented alongside the Fio2. [Grade D]
  • (R31) A copy of the clinical notes and observations should be left in the patient's home. [Grade D]
  • (R32) Serial spirometry may be useful as objective confirmation of improvement or worsening during an exacerbation and should always be measured before discharge. [Grade D]
  • (R33) Treatment compliance and nebuliser/oxygen usage should be assessed. [Grade D]
  • (R34) Telephone contact with respiratory practitioner should be encouraged. [Grade D]
  • (R35) Weekly team meetings should be held. [Grade D]

Duration of hospital/home care and number of visits

The duration of home care has varied considerably in the published studies, from 3.56 days6 to 24 days,7 with a mean value of 11 days. The number of visits varied from 3.83 to 11.4,7 In one study the intervention was considered to have failed if more than five visits were required.6 These parameters are obviously influenced by the experience and confidence of the practitioners. There is no evidence that the outcomes were affected by the duration of care or by the number of visits.

In the 2nd UK COPD audit37 the median length of stay in hospitals with access to ESD was 4 days compared with 7 days where there was no ESD. The median length of stay in the ESD scheme was 11 days (hospital time + ESD time). [Level of evidence III]

Recommendations

  • (R36) Home care should be completed in fewer than 14 days and with fewer than 10 visits. [Grade C]
  • (R37) Failure to comply with the above recommendation requires team discussion. [Grade C]

Understanding ESD

Three important points arose from a recent qualitative study which was aimed at evaluating a COPD supported discharge scheme (Clarke et al, unpublished, 2005):

  1. Hospital managers and staff should agree precise aims and objectives of the service.
  2. Patients should understand why the service was set up, the meaning of supported discharge and the necessity of home visits by respiratory practitioners.
  3. The discharge process was often similar to that for ordinary discharges and included long waits for transport and delays in getting drugs from pharmacy, despite HaH patients technically still being within a period of secondary care. [Level of evidence IV]

Recommendations

  • (R38) There should be written agreement between management and medical/nursing staff defining the scope and objectives of an ESD service. [Grade D]
  • (R39) Patients should be given an information leaflet about the service, as shown in Appendix 2. [Grade D]
  • (R40) The process of discharge should be streamlined. [Grade D]

Telemetry

A home telecare system was found to be time consuming for staff as they had to familiarise themselves with the equipment and this was a barrier to its implementation. Procurement and user‐friendliness of equipment were problematical.43,44,45 A review of cost effectiveness in telemedicine found that the literature was limited and the methodology seriously flawed.46 This view was confirmed in a systematic review where only 4% of 600 studies met the criteria for inclusion in a formalised quality review.47[Level of evidence III]

Recommendation

  • (R41) There is insufficient evidence to justify setting up telemetry in HaH at present. [Grade C]

Economics of service provision

The published HaH studies have largely been performed in inner city teaching hospitals. Two of the randomised trials of HaH have included economic evaluations of the intervention. In the Edinburgh study the estimated average cost to the health service of patients in the HaH group was £877 per exacerbation compared with £1753 in the control group.3 Similar findings were reported in the Barcelona study where the average health care cost of HaH patients was 62% less than that of the control patients.6 Difficulty in obtaining funding was the primary reason for inability to set up a HaH scheme for COPD among UK physicians.38 Further more detailed health economic evaluations are required to inform healthcare providers of the cost implications of HaH for COPD exacerbations, but the evidence to date does suggest that a cost benefit is likely. A sample business case is shown in Appendix 3. [Level of evidence III]

Recommendation

  • (R42) Plans for new HaH services should include formal health economics evaluation. [Grade C]

Treatment

In determining the evidence base for recommending treatment strategies in the context of HaH, it is important to be aware of the following factors.

The available evidence base is derived from the study of treatments either performed in an outpatient or hospital setting, not HaH. Certain treatment modalities cannot be delivered in a HaH setting for practical or safety reasons. No reference is therefore made to the utility of some treatments (including intravenous therapies such as theophyllines, magnesium, antibiotics, doxapram or the application of assisted ventilation).

The NICE guidelines2 have comprehensively reviewed the evidence base for treatments used in exacerbations of COPD. Here we aim to summarise the available guidance and highlight aspects relevant to HaH.

It is expected that all patients will be considered for potential treatment at home with the following modalities: bronchodilators (inhaler or nebulised), oral corticosteroids, oral antibiotics and oxygen. Some patients may have access to physiotherapy in the HaH setting.

When and how to give bronchodilators?

Short‐acting bronchodilators (β agonists or anticholinergics) are effective in increasing FEV1 and reducing breathlessness.2 These can be given in combination and have effects that last between 4 and 6 hours and therefore need to be administered regularly at the time of exacerbation.

Bronchodilators can effectively be administered by nebulisers or hand‐held inhalers.2 Nebulised treatments are more convenient to administer as supervision of up to 20 inhalations of a hand‐held inhaler would be necessary to produce a similar effect to one nebuliser.48 Nebulised delivery of bronchodilator was the standard treatment for most patients enrolled in controlled trials of HaH.3,4,5,7,42[Level of evidence NICE]

Recommendations

  • (R43) Regular administration of short‐acting broncho‐ dilators (β agonist/anticholinergic or both) should be administered to all patients during HaH care. [Grade NICE]
  • (R44) Nebulised delivery is the mode of choice in HaH. [Grade C]

Who should receive corticosteroids?

Well conducted trials have established a role for corticosteroid therapy in COPD exacerbations.49,50,51 Rates of treatment failure decrease and duration of hospital stay is reduced by approximately 2 days after corticosteroid administration.

In the randomised trials, a significant number of patients developed glycosuria or required treatment for hyperglycaemia. Employing HaH limits the approaches that can be taken to control hyperglycaemia induced by prednisolone. Particular attention should be paid to diabetics who are prescribed corticosteroids during home care.

The NICE guidelines have proposed the use of prednisolone at 30 mg for 7–14 days in all those hospitalised with an exacerbation and its consideration in outpatients with an exacerbation who can tolerate prednisolone.2 Since HaH patients would be hospitalised if the service did not exist, it is reasonable that they should all be prescribed corticosteroids. [Level of evidence NICE]

Recommendation

  • (R45) Prednisolone 30 mg/daily should be given for 7–14 days to all patients unless there is a specific contraindication to steroid therapy. [Grade NICE]

Who should be given oxygen?

Oxygenation deteriorates unpredictably during an exacerbation.52 Oxygen administration improves arterial oxygenation and relieves symptoms including breathlessness.53 It is considered that oxygen saturations greater than 90% and less than 94% are optimal and that this is usually achievable with 2 or 4 litres by nasal cannula, or by 24% or 28% by Venturi mask.52 The target oxygenation (90–93%), not mode of delivery, is prescribed in the NICE and joint ATS/ERS COPD guidelines.2,54

Arterial blood gas measurement is necessary to assess the initial response to oxygen therapy and to monitor for worsening hypercapnia with repetition after 1 h.2 Oxygen saturation monitors can be used to monitor the continuing need for oxygen at home. HaH services which were part of randomised trials have provided concentrator or cylinder oxygen to patients.3,4,5,7,42 It may not be possible to withdraw oxygen from all patients, hypoxic during exacerbation, when they have sufficiently recovered to be discharged from HaH back to primary care.55[Level of evidence III]

Recommendations

  • (R46) Oxygen therapy is a cornerstone of treatment of an exacerbation of COPD and should be made available to patients if they are hypoxaemic. [Grade C]
  • (R47) Supplementary oxygen should be administered in a controlled fashion aiming for 90% <Spo2 <94%. [Grade C]
  • (R48) Patients who remain in respiratory failure should be referred for consideration of long term oxygen therapy. [Grade C]

Who should receive antibiotics?

It has been shown that those with two or more symptoms of an exacerbation (purulent sputum, increased sputum and increased breathlessness) benefit from antibiotic therapy.56,57 The NICE guidelines recommend the use of antibiotics for those with a history of more purulent sputum, but do not stratify patients towards differing antibiotic therapy.2[Level of evidence NICE]

With severe disease, pathogens such as Staphylococcus and Pseudomonas become more likely and beta lactam resistant organisms are more prevalent in those with multiple antibiotic courses.57,58 Risk factors for treatment failure include increased exacerbation frequency, severe FEV1 impairment, co‐morbidity and increasing age.58 It is therefore logical to avoid repeating similar antibiotics in those with recurrent requirements for treatment. [Level of evidence 1b]

Recommendations

  • (R49) Antibiotic therapy should be offered to patients with two or more of breathlessness, increased sputum and increased sputum purulence. [Grade A]
  • (R50) Patients with a high risk of treatment failure or unusual pathogens benefit from tailored antibiotic therapy. [Grade B]

What other treatments can be offered?

HaH interventions provide the opportunity to offer additional ancillary treatments to the patient. Although components of care such as smoking cessation and pulmonary rehabilitation were not offered as part of the studies forming the evidence base of HaH for COPD, these form part of basic COPD care delivery. Additional support for patients and carers may be provided by home help and occupational therapy services.

Positioning to improve the mechanics of breathing has been shown to improve breathlessness and respiratory muscle strength.59 The use of positive expiratory pressure masks led to greater sputum clearance in a randomised trial.60 Acute administration of nutritional support has been shown to be feasible during exacerbation, but with no clear benefit proven.61 Pulmonary rehabilitation begun in the aftermath of an exacerbation results in improvement in exercise capacity and quality of life evident 6 months after an initial hospital‐based programme.62[Level of evidence 1b]

Recommendations

  • (R51) HaH should not prevent patients gaining access to broader COPD care such as pulmonary rehabilitation or smoking cessation programmes. [Grade D]
  • (R52) Selected physiotherapeutic techniques and nutritional support may be beneficial. [Grade D]

Intermediate care in stable COPD

Two systematic reviews have studied the efficacy of chronic disease management programmes for stable COPD.63,64 The individual RCTs included in these systematic reviews were performed in different countries and there were some differences between the subgroups of COPD patients.

In 2001 a Cochrane systematic review of home care for COPD concluded that it “is an expensive form of care that has not been shown to improve lung function. There may be some benefits for people with less severe disease, but more research is needed to demonstrate this”.63 The most recent systematic review concluded that “there is little evidence to support the widespread implementation of nurse led management interventions for COPD, but the data are too sparse to exclude any clinically relevant benefit or harm arising from such interventions”.64 A recent ATS statement concurs: “Many home health interventions are based on empirical recommendations rather than research data”.65

Components of the interventions

The components of home care/chronic disease management interventions for stable COPD patients may include:

  • An education programme with information on the following topics:
    • the disease and its management;
    • control of symptoms;
    • encouragement and help to stop smoking;
    • plan of action for acute exacerbations;
    • adopting a healthy lifestyle;
    • leisure activities and travelling;
    • long term oxygen therapy if appropriate.
  • An exercise programme.
  • A contact list for advice on acute emergencies.
  • Prescriptions at home to initiate when an exacerbation occurs.
  • Follow‐up visits at home or hospital or in the community.
  • Psychological support.
  • Support, advice and education for carers.

The relative importance of each component may vary according to the perspective of the patient, carer and health professional. We present the evidence relevant to the following questions, from the RCTs included in the two systematic reviews (together with RCTs published more recently):

  • Do they improve quality of life?
  • Do they improve objective measurements of pulmonary function or patient mortality?
  • Do they alter the frequency of unscheduled visits to the GP or hospital A&E departments?
  • Do they alter the frequency of hospital admissions?
  • Do they depend on any particular type of intervention for their success?

Do the schemes improve the quality of life?

Several different types of health related quality of life (HRQoL) questionnaires have been used to measure this important outcome. The commonest measure has been the SGRQ. None of the RCTs of chronic disease management/home care schemes has demonstrated a significant improvement in total SGRQ with the intervention. Some statistically significant differences have been seen in individual components of the SGRQ, but their clinical significance is unclear.

There is currently no evidence to suggest that these interventions improve patients' HRQoL as measured by total SGRQ score. [Level of evidence 1a]

Recommendation

  • (R53) New and established schemes should include a validated tool to assess impact on patients' HRQoL. [Grade D]

Do the schemes improve objective measurements of pulmonary function or patient mortality?

There is no evidence that the 6 minute walking test was improved in any of the three schemes where this parameter was measured.65,66,67,68 Patients not looked after by a respiratory health worker had a higher chance of dying (relative risk 2.9, confidence limits 0.8 to 10.2) in one study,67 but the other studies have found no such effect and a meta‐analysis of the effect on mortality found no significant improvement in the intervention patients.64

There is no available evidence to suggest that such schemes alter pulmonary function or influence mortality rates. [Level of evidence 1a]

Do the schemes alter the frequency of hospital admissions or unscheduled visits to the GP or A&E departments?

Researchers from Spain and Quebec have demonstrated reductions in the frequency of unscheduled visits to hospital A&E departments at 1 year66,69 and 2 years follow‐up70 with their chronic disease management schemes. In the Canadian study there was also a significant reduction in unscheduled visits to the family physician at 12 months in the intervention group.66 The Spanish study only included patients receiving long term oxygen therapy,69 whereas the other study involved patients with at least one hospital admission for an acute exacerbation of COPD in the 12 months before entry into the scheme.66,70

These two studies also demonstrated a significant reduction in hospital admissions from all causes in the intervention groups. The Canadian study reported a 40% reduction in admissions for an acute exacerbation, a 57% reduction in admissions for other health problems at 12 months,66 and a 27% reduction in all cause admissions at 2 years.70

Patients in the Spanish study had a significant reduction in hospital stay (7.43 vs 18.2 days).69 Similar findings were reported from the Quebec study (7.2 vs 12.5 days).66 However, several other RCTs have failed to detect or report any benefit in terms of unscheduled visits to the GP,71 visits to A&E departments,72,73 hospital admissions,67,71,72,74,75 or length of hospital stay.73 Overall, the trials defy meta‐analysis due to their differing presentation of results.

The available evidence is conflicting and it is not clear whether these interventions reduce hospital admissions, unscheduled visits to the family physician/GP or attendance at A&E departments. [Level of evidence 1a]

Recommendations

  • (R54) Further robust studies are required to assess whether chronic disease management interventions improve patient outcomes in terms of hospital re‐admission, A&E attendance or unscheduled GP/family physician attendance. [Grade D]
  • (R55) The Spanish study of patients on long term oxygen therapy needs to be repeated as it may have identified a subgroup of patients who experience particular benefits from this kind of intervention. [Grade D]

Audit

The outcome measures in HaH are well described in the various RCTs and show considerable concordance.3,4,5,6,7 It is therefore possible for all schemes to incorporate an audit tool to assess performance against an accepted standard.

Suggested audit criteria:

  • Proportion of patients with exacerbations accepted for HaH.
  • Proportion of patients accepted despite satisfying absolute criteria for exclusion from HaH.
  • Proportion of patients readmitted/admitted to hospital from HaH.
  • Reduction in duration of hospital stay.
  • Mortality rate during HaH and within 3 months of HaH episode.
  • Readmission rate within 3 months of HaH episode.
  • Patient and carer satisfaction.

Appendix 1 Guideline Development Group

Members of the Guideline Development Group:

Robin Stevenson—Chair, Consultant Respiratory Physician, Glasgow Royal Infirmary

Robert Angus, Consultant Respiratory Physician, University Hospital Aintree, Liverpool

Maria Blanchard, Consultant Physiotherapist, Central Middlesex and Northwick Park

Julia Bott, Consultant Physiotherapist, North Surrey PCT

Christina Collins‐Gilchrist, Clinical Specialist Physiotherapist, Maidstone & Tunbridge Wells

Anthony Davison, Consultant Respiratory Physician, Southend Hospital, Essex

Kate Ford, Clinical Specialist Physiotherapist, Bristol Royal Infirmary

Jonathan Fuld, Specialist Registrar, Cambridge

Martin Johnson, Consultant Respiratory Physician, Western Infirmary, Glasgow

Noel O'Kelly, General Practitioner (GPwSI)—Respiratory Medicine, East Lincolnshire PCT

John O'Reilly, Consultant Respiratory Physician, University Hospital Aintree, Liverpool

Kelly Redden‐Rowley, Respiratory Clinical Specialist in Physiotherapy, Sandwell Primary Care Trust

Jane Scullion, Consultant Respiratory Nurse, Glenfield Hospital, Leicester

Rebecca Sherrington, Clinical Nurse Specialist, Respiratory Medicine, Princess Elizabeth Hospital, Guernsey

Stephanie Taylor, Senior Clinical Lecturer, Health Services R&D, Barts and The London, Queen Mary's School of Medicine and Dentistry

Pamela Vaughn, Clinical Specialist Physiotherapist, Glasgow Royal Infirmary

John Williams, Consultant Respiratory Physician, Halton General Hospital

Appendix 2 Hospital‐at‐Home Patient Information

You have a flare‐up of your chest condition, chronic obstructive pulmonary disease (COPD). We have decided that you do not need to stay in hospital and that you can go home on the treatment which has been prescribed for you. This includes drugs you inhale with your nebuliser, steroid and antibiotic tablets and oxygen if your blood oxygen level is low. This treatment package will go home with you.

It is accepted that this treatment can be taken safely at home and the outcome is just as good, if not better, than if you had remained in hospital. You can expect to recover in a week or two and return to your normal state of health.

Your treatment will be supervised at home by one of our respiratory nurses or physiotherapists who will visit you on the day after you go home and will continue to visit you until you have almost fully recovered. At the visits your progress will be monitored and your treatment will be adjusted if necessary. In the unlikely event that you do not improve as expected, you will be admitted to hospital for further tests and a change of treatment.

The nurse or physiotherapist will leave details in the house of your illness and the treatment which you are taking in case your GP comes to see you. She will also leave her mobile phone number and you can call her at any time for advice or reassurance.

If you have been lent a nebuliser, it will be taken back if you no longer need it. However, if it remains useful, you will be provided with one for long term use. Similarly, if you need oxygen and if your blood oxygen level remains low, we will arrange for you to have an oxygen concentrator again for long term use.

During your care at home, we will consider what can be done to improve your health so that further flare‐ups will be less likely to happen. This might include advice on quitting smoking, exercises, dietary changes and information about COPD which will help you to cope better with your illness. Understanding COPD lets you recognise when things are going wrong and enables you to step up your treatment at an early stage to prevent further deterioration.

Appendix 3 Business case

Table thumbnail

Footnotes

*Members of the Guideline Development Group are listed in Appendix 1.

References

1. Ram F S F, Wedzicha J A, Wright J. et al Hospital at home for acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ 2004. 329315–318.318 [PMC free article] [PubMed]
2. National Collaborating Centre for Chronic Conditions Chronic obstructive pulmonary disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004. 59(Suppl I)1–232.232 [PMC free article] [PubMed]
3. Skwarska E, Cohen G, Skwarski K M. et al Randomized controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax 2000. 55907–912.912 [PMC free article] [PubMed]
4. Davies L, Wilkinson M, Bonner S. et al “Hospital at home” versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. BMJ 2000. 3211265–1268.1268 [PMC free article] [PubMed]
5. Ojoo J C, Moon T, McGlone S. et al Patients' and carers' preferences in two models of care for acute exacerbations of COPD: results of a randomised controlled trial. Thorax 2002. 57167–169.169 [PMC free article] [PubMed]
6. Hernandez C, Casas A, Escarrabill J. et al Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003. 2158–67.67 [PubMed]
7. Cotton M M, Bucknall C E, Dagg K D. et al Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Thorax 2000. 55902–906.906 [PMC free article] [PubMed]
8. Dowsey M M, Kilgour M L, Santamaria N M. et al Clinical pathways in hip and knee arthroplasty: a prospective randomised controlled study. Med J Aust 1999. 17059–62.62 [PubMed]
9. Choong P F, Langford A K, Dowsey M M. et al Clinical pathway for fractured neck of femur: a prospective, controlled study. Med J Aust 2000. 172423–426.426 [PubMed]
10. Johnson K B, Blaisdell C J, Walker A. et al Effectiveness of a clinical pathway for inpatient asthma management. Pediatrics 2000. 1061006–1012.1012 [PubMed]
11. Marrie T J, Lau C Y, Wheeler S L. et al A controlled trial of a critical pathway for treatment of community‐acquired pneumonia. CAPITAL Study Investigators. Community‐Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000. 283749–755.755 [PubMed]
12. Sulch D, Perez I, Melbourn A. et al Randomized controlled trial of integrated (managed) care pathway for stroke rehabilitation. Stroke 2000. 311929–1934.1934 [PubMed]
13. Kasper E K, Gerstenblith G, Hefter G. et al A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002. 39471–480.480 [PubMed]
14. McCrory D C, Brown C, Gelfand S E. et al Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001. 1191190 [PubMed]
15. Ball P, Harris J M, Lowson D. et al Acute infective exacerbations of chronic bronchitis. QJM 1995. 8861–68.68 [PubMed]
16. Dewan N A, Rafique S, Kanwar B. et al Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000. 117662–671.671 [PubMed]
17. Seemungal T A, Donaldson G C, Paul E A. et al Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998. 1571418–1422.1422 [PubMed]
18. Miravitlles M, Espinosa C, Fernandez‐Laso E. et al Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999. 11640–46.46 [PubMed]
19. Miravitlles M, Guerrero T, Mayordomo C. et al Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000. 67495–501.501 [PubMed]
20. Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J 2001. 17928–933.933 [PubMed]
21. Adams S G, Melo J, Luther M. et al Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000. 1171345–1352.1352 [PubMed]
22. Antonelli I, Fuso L, De Rosa M. et al Co‐morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997. 102794–2800.2800 [PubMed]
23. Kessler R, Faller M, Fourgaut G. et al Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999. 159158–164.164 [PubMed]
24. Garcia‐Aymerich J, Monso E, Marrades R M. et al Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med 2001. 1641002–1007.1007 [PubMed]
25. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996. 1531530–1535.1535 [PubMed]
26. Balter M S, La Forge J, Low D E. et al Canadian guidelines for the management of acute exacerbation of chronic bronchitis: executive summary. Can Respir J 2003. 103–32B.32B
27. Gravil J H, Al Rawas O A, Cotton M M. et al Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. Lancet 1998. 3511853–1855.1855 [PubMed]
28. Nicholson C, Bowler S, Jackson C. et al Cost comparison of hospital‐ and home‐based treatment models for acute chronic obstructive pulmonary disease. Aust Health Rev 2001. 24181–187.187 [PubMed]
29. Monso E, Ruiz J, Rosell A. et al Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995. 1521316–1320.1320 [PubMed]
30. Stockley R A, O'Brien C, Pye A. et al Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000. 1171638–1645.1645 [PubMed]
31. Sherman S, Skoney J A, Ravikrishnan K P. Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value. Arch Intern Med 1989. 1492493–2496.2496 [PubMed]
32. Emerman C L, Cydulka R K. Evaluation of high‐yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1993. 22680–684.684 [PubMed]
33. Tsai T W, Gallagher E J, Lombardi G. et al Guidelines for the selective ordering of admission chest radiography in adult obstructive airway disease. Ann Emerg Med 1993. 221854–1858.1858 [PubMed]
34. Connors A F, Dawson N V, Thomas C. et al Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996. 154959–967.967 [PubMed]
35. Williams J G, for Halton Rapid Response Respiratory Team P15 hospital assessment is not required for home care of COPD exacerbation (abstract). Thorax 2004. 59(Suppl II)ii47
36. Davison A G, Monaghan M, Brown D. et al Hospital at home for chronic obstructive pulmonary disease—an integrated hospital and community based generic intermediate care service for prevention and early discharge. Chronic Respir Dis 2006. 3181–185.185 [PubMed]
37. Quantrill S J, Hosker H, Anstey K. et al S96 efficacy and organisation of early discharge schemes for acute exacerbations of chronic obstructive pulmonary disease: analysis from the 2nd UK COPD audit (abstract). Thorax 2005. 60(Suppl 2)ii34
38. Johnson M K, Flanigan U, Fuld J. et al Hospital at home services for acute exacerbation of chronic obstructive pulmonary disease: a survey of British practice. Health Bull 2001. 59163–170.170 [PubMed]
39. Shepperd S, Harwood D, Jenkinson C. et al Randomised controlled trial comparing hospital at home care with inpatient hospital care. I: Three month follow up of health outcomes, BMJ 1998. 3161786–1791.1791 [PMC free article] [PubMed]
40. Wood‐Baker R, Walters E H. Corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Syst Rev 2000. (2)CD001288 [PubMed]
41. Niewoehner D E, Collins D. Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med 2000. 1611201–1205.1205 [PubMed]
42. Sala E, Alegre L, Carrera M. et al Supported discharge shortens hospital stay in patients hospitalized because of an exacerbation of COPD. Eur Respir J 2001. 171138–1142.1142 [PubMed]
43. Mair F S, Wilkinson M, Bonnar S A. et al The role of telecare in the management of exacerbations of chronic obstructive pulmonary disease in the home. J Telemed Telecare 1999. 5(Suppl 1)S66–S67.S67 [PubMed]
44. Mair F, Boland A, Angus R. et al A randomized controlled trial of home telecare. J Telemed Telecare 2002. 8(Suppl 2)S58–S60.S60 [PubMed]
45. Hibbert D, Mair F S, Angus R M. et al Lessons from the implementation of a home telecare service. J Telemed Telecare 2003. 9(Suppl 1)S55–S56.S56 [PubMed]
46. Mair F S, Haycox A, May C. et al A review of telemedicine cost‐effectiveness studies. J Telemed Telecare 2000. 6(Suppl 1)S38–S40.S40 [PubMed]
47. Whitten P S, Mair F S, Haycox A. et al Systematic review of cost effectiveness studies of telemedicine interventions. BMJ 2002. 3241434–1437.1437 [PMC free article] [PubMed]
48. O'Driscoll B R. Nebulisers for chronic obstructive pulmonary disease. Thorax 1997. 52(Suppl 2)49–52S.52S [PMC free article] [PubMed]
49. Davies L, Angus R M, Calverley P M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999. 354456–460.460 [PubMed]
50. Niewoehner D E, Erbland M L, Deupree R H. et al Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999. 3401941–1947.1947 [PubMed]
51. Thompson W H, Nielson C P, Carvalho P. et al Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996. 154407–412.412 [PubMed]
52. Agusti A G, Carrera M, Barbe F. et al Oxygen therapy during exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999. 14934–939.939 [PubMed]
53. Swinburn C R, Mould H, Stone T N. et al Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis 1991. 143913–915.915 [PubMed]
54. Celli B R, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004. 23932–946.946 [PubMed]
55. Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980. 93391–398.398 [PubMed]
56. Anthonisen N R, Manfreda J, Warren C P. et al Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987. 106196–204.204 [PubMed]
57. Russo R L, D'Aprile M. Role of antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Pharmacother 2001. 35576–581.581 [PubMed]
58. O'Donnell D E, Aaron S, Bourbeau J. et al Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease. Can Respir J 2003. 10(Suppl A)11–65A.65A [PubMed]
59. O'Neill S, McCarthy D S. Postural relief of dyspnoea in severe chronic airflow limitation: relationship to respiratory muscle strength. Thorax 1983. 38595–600.600 [PMC free article] [PubMed]
60. Bellone A, Spagnolatti L, Massobrio M. et al Short‐term effects of expiration under positive pressure in patients with acute exacerbation of chronic obstructive pulmonary disease and mild acidosis requiring non‐invasive positive pressure ventilation. Intensive Care Med 2002. 28581–585.585 [PubMed]
61. Saudny‐Unterberger H, Martin J G, Gray‐Donald K. Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997. 156794–799.799 [PubMed]
62. Man W D C, Polkey M I, Donaldson N. et al Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ 2004. 3291209–1211.1211 [PMC free article] [PubMed]
63. Smith B, Appleton S, Adams R. et al Home care by outreach nursing for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000. 2CD000994 [PubMed]
64. Taylor S J C, Candy B, Bryar R M. et al Effectiveness of innovations in nurse led chronic disease management for patients with chronic obstructive pulmonary disease: systematic review of evidence. BMJ 2005. 331485–488.488 [PMC free article] [PubMed]
65. American Thoracic Society Statement on home care for patients with respiratory disorders. Am J Respir Crit Care Med 2005. 1711443–1464.1464 [PubMed]
66. Bourbeau J, Julien M, Maltais F. et al Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease‐specific self‐management intervention. Arch Intern Med 2003. 163585–591.591 [PubMed]
67. Littlejohns P, Baveystock C M, Parnell H. et al Randomised controlled trial of the effectiveness of a respiratory health worker in reducing impairment, disability, and handicap due to chronic airflow limitation. Thorax 1991. 46559–564.564 [PMC free article] [PubMed]
68. Monninkhof E, van der Valk P, van der Palen J. et al Self‐management education for patients with chronic obstructive pulmonary disease: a systematic review. Thorax 2003. 58394–398.398 [PMC free article] [PubMed]
69. Farrero E, Escarrabill J, Prats E. et al Impact of a hospital‐based home‐care program on the management of COPD patients receiving long‐term oxygen therapy. Chest 2001. 119364–369.369 [PubMed]
70. Gadoury M A, Schwartzman K, Rouleau M. et al Self‐management reduces both short‐ and long‐term hospitalisation in COPD. Eur Respir J 2005. 26853–857.857 [PubMed]
71. Coultas D, Frederick J, Barnett B. et al A randomized trial of two types of nurse‐assisted home care for patients with COPD. Chest 2005. 1282017–2024.2024 [PubMed]
72. Hermiz O, Comino E, Marks G. et al Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease. BMJ 2002. 325938–942.942 [PMC free article] [PubMed]
73. Smith B J, Appleton S L, Bennett P W. et al The effect of a respiratory home nurse intervention in patients with chronic obstructive pulmonary disease (COPD). Aust NZ J Med 1999. 29718–725.725 [PubMed]
74. Egan E, Clavarino A, Burridge L. et al A randomized control trial of nursing‐based case management for patients with chronic obstructive pulmonary disease. Lippincott's Case Management 2002. 7170–179.179 [PubMed]
75. Cockcroft A, Bagnall P, Heslop A. Controlled trial of respiratory health worker visiting patients with chronic respiratory disability. BMJ 1987. 294225–228.228 [PMC free article] [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...